1. Risk of renal adverse effects from tenofovir alafenamide

   Unknown 02 April 2022 Pages: 1 - 1

2. Shoulder pain and inflammation after vaccination in upper arm

   News item 02 April 2022 Pages: 2 - 2

3. Voluntary recall of SYMJEPI epinephrine injection in the US for potential manufacturing defect

   News item 02 April 2022 Pages: 3 - 3

4. Best regimen for elexacaftor/ivacaftor/tezacaftor with nirmatrelvir-ritonavir for COVID-19?

   Clinical study 02 April 2022 Pages: 4 - 4

5. Concomitant tizanidine and ciprofloxacin increases risk of hypotension

   Unknown 02 April 2022 Pages: 5 - 5

6. Dapagliflozin associated with higher risk of ketoacidosis in T2DM patients

   Unknown 02 April 2022 Pages: 6 - 6

7. Different safety profiles for SGLT-2 vs SGLT-1/2 inhibitors for T2DM

   Unknown 02 April 2022 Pages: 7 - 7

8. Dupiliumab-related ocular AEs in patients with atopic dermatitis

   Clinical study 02 April 2022 Pages: 8 - 8

9. Mirtazapine use safe during pregnancy

   Clinical study 02 April 2022 Pages: 9 - 9

10. Myocarditis after third dose of Pfizer-BioNTech COVID-19 vaccine

    Clinical study 02 April 2022 Pages: 10 - 10

11. No safety signal after COVID-19 vaccination for immune-mediated neurological events

    Clinical study 02 April 2022 Pages: 11 - 11

12. Sodium channel-blocking anticonvulsants do not increase risk of cardiac arrest

    Clinical study 02 April 2022 Pages: 12 - 12

13. Other adverse reaction research

    News item 02 April 2022 Pages: 13 - 13

14. Abiraterone/docetaxel

    Case report 02 April 2022 Pages: 14 - 14

15. Acenocoumarol

    Case report 02 April 2022 Pages: 15 - 15

16. Acetylcysteine

    Case report 02 April 2022 Pages: 16 - 16

17. Ad26.COV2-S

    Case report 02 April 2022 Pages: 17 - 17

18. Adalimumab/tocilizumab

    Case report 02 April 2022 Pages: 18 - 18

19. Adenosine

    Case report 02 April 2022 Pages: 19 - 19

20. Alemtuzumab

    Case report 02 April 2022 Pages: 20 - 20

21. Alemtuzumab

    Case report 02 April 2022 Pages: 21 - 21

22. Alpelisib

    Case report 02 April 2022 Pages: 22 - 22

23. Alteplase/heparin

    Case report 02 April 2022 Pages: 23 - 23

24. Amantadine/levodopa/carbidopa

    Case report 02 April 2022 Pages: 24 - 24

25. Amiodarone

    Case report 02 April 2022 Pages: 25 - 25

26. Amiodarone/methylprednisolone/gammaglobulin

    Case report 02 April 2022 Pages: 26 - 26

27. Amiodarone/metoprolol-tartrate

    Case report 02 April 2022 Pages: 27 - 27

28. Amiodarone/metoprolol/phenylephrine

    Case report 02 April 2022 Pages: 28 - 28

29. Amiodarone/propranolol/thiamazole

    Case report 02 April 2022 Pages: 29 - 29

30. Amodiaquine/artesunate

    Case report 02 April 2022 Pages: 30 - 30

31. Amoxicillin/clavulanic-acid

    Case report 02 April 2022 Pages: 31 - 31

32. Amoxicillin/clavulanic-acid

    Case report 02 April 2022 Pages: 32 - 32

33. Anti-infectives/immunosuppressants

    Case report 02 April 2022 Pages: 33 - 33

34. Anti-inflammatories/antineoplastics

    Case report 02 April 2022 Pages: 34 - 34

35. Antibacterials/antifungals

    Case report 02 April 2022 Pages: 35 - 35

36. Antibacterials/immunosuppressants

    Case report 02 April 2022 Pages: 36 - 36

37. Antiepileptic drugs

    Case report 02 April 2022 Pages: 37 - 37

38. Antiepileptic-drugs

    Case report 02 April 2022 Pages: 38 - 38

39. Antifungals/antithymocyte-globulin/methylprednisolone

    Case report 02 April 2022 Pages: 39 - 39

40. Antihistamines/mast-cell-stabilisers/midostaurin

    Case report 02 April 2022 Pages: 40 - 40

41. Antihypertensives/ibuprofen

    Case report 02 April 2022 Pages: 41 - 41

42. Antineoplastic drugs

    Case report 02 April 2022 Pages: 42 - 42

43. Antineoplastics

    Case report 02 April 2022 Pages: 43 - 43

44. Antineoplastics

    Case report 02 April 2022 Pages: 44 - 44

45. Antineoplastics

    Case report 02 April 2022 Pages: 45 - 45

46. Antineoplastics

    Case report 02 April 2022 Pages: 46 - 46

47. Antineoplastics

    Case report 02 April 2022 Pages: 47 - 47

48. Antineoplastics

    Case report 02 April 2022 Pages: 48 - 48

49. Antineoplastics

    Case report 02 April 2022 Pages: 49 - 49

50. Antineoplastics

    Case report 02 April 2022 Pages: 50 - 50